KEY POINTS
- This retrospective single-center study included 196 patients receiving salvage radiotherapy after radical prostatectomy between 2005 and 2013, excluding metastatic disease, pathological nodal involvement and prior adjuvant RT. Median follow-up was 109.5 months, median prescribed dose was 70.2 Gy, and 46 patients (23.5%) received androgen deprivation therapy; pelvic nodal RT was delivered selectively according to treating-physician judgment.
- Pre-salvage PSA was strongly associated with subsequent biochemical outcomes. Patients initiating RT at PSA >0.2 ng/mL experienced worse biochemical progression-free survival than those treated at PSA ≤0.2 ng/mL (HR 1.77, 95% CI 1.14–2.73; p=0.010). After adjustment, the association persisted (HR 1.96, 95% CI 1.24–3.11; p=0.004), supporting earlier salvage treatment in appropriate patients.
- Pathological characteristics also predicted biochemical failure. Positive surgical margins were associated with improved biochemical control after salvage RT (adjusted HR 0.63, 95% CI 0.41–0.97; p=0.039), whereas higher Gleason score (HR 1.57; p=0.001) and higher pathological T stage (HR 1.38; p=0.013) were associated with increased recurrence risk. This suggests that recurrence after negative-margin surgery may be less likely to reflect disease confined to the prostate bed.
- Across the full cohort, adding pelvic nodal irradiation was not significantly associated with improved biochemical progression-free survival (HR 0.78; p=0.299). However, among patients with negative surgical margins, pelvic nodal treatment was associated with better biochemical outcomes (HR 0.45, 95% CI 0.22–0.90; p=0.024), whereas no significant association was observed in margin-positive patients (HR 1.47; p=0.240).
- The negative-margin subgroup also showed a marked difference in immediate biochemical response. PSA-response failure occurred in 4.5% of patients receiving prostate-bed plus pelvic nodal RT compared with 31.7% receiving prostate-bed irradiation alone (p=0.010). In contrast, corresponding rates among margin-positive patients were 12.5% versus 9.6%, without a significant difference.
- Pelvic nodal RT was independently associated with improved regional nodal recurrence-free survival across the overall cohort (adjusted HR 0.29, 95% CI 0.10–0.88; p=0.028). Although margin-negative patients also showed a favorable numerical trend in nodal control, the subgroup-specific association was not statistically significant; pelvic nodal irradiation was not independently associated with improved distant metastasis-free survival in the aggregate analysis.
- These findings require substantial caution because treatment allocation was nonrandomized, PSMA-PET was unavailable during the treatment era, and both nodal irradiation and ADT were selected according to clinical judgment. No multiplicity adjustment was applied to the numerous exploratory subgroup analyses, and the study cannot establish whether margin status truly predicts a differential treatment effect from pelvic nodal irradiation.
CLINICAL TAKEAWAY
Earlier salvage RT at lower PSA levels is supported by the observed long-term associations, while negative surgical margins may identify patients in whom occult regional disease contributes more strongly to recurrence. The apparent benefit of pelvic nodal irradiation in margin-negative patients is hypothesis-generating and should be interpreted alongside randomized SPPORT evidence, modern PSMA-PET staging and individual recurrence risk rather than used as an independent treatment-selection rule.